Stocks · News reference

ADMA Biologics Says Three-Lot Study Shows Updated IVIG Process Removes Clot-Linked Impurities, Raises Yield; No Clotting Events Reported Through July 2026

Oct 15, 2026, 11:05 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 15, 2026, 2:20 PMBenzinga Newsdesk
ADMA Biologics shares are trading higher after the company announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the company’s optimized, proprietary intravenous immune globulin manufacturing process.
ADMA
BenzingaAug 5, 2026, 8:24 PMBenzinga Newsdesk
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
ADMA
BenzingaAug 5, 2026, 8:14 PMBenzinga Newsdesk
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from
ADMA